文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

加速期骨髓纤维化的减低强度造血干细胞移植

Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis.
PubMed 文献 · Blood Adv · 2022-01-01

本研究分析349例原发或继发骨髓纤维化接受减低强度移植的患者,其中35例为加速期骨髓纤维化。中位随访5.9年,加速期组5年总生存率65%与慢性期组64%无显著差异(P=0.91),但加速期组5年复发率30%高于慢性期组15%(P=0.02)。

要点

  • 加速期骨髓纤维化减低强度移植后5年总生存率65%,与慢性期64%无显著差异。
  • 加速期组5年复发率30%,高于慢性期组15%,差异有统计学意义。
  • 加速期组5年无复发生存率49%与慢性期组55%无显著差异。

核心结论

  • 减低强度移植在加速期骨髓纤维化中显示出良好的生存,但复发率高于慢性期骨髓纤维化。

研究设计与样本

  • 分析349例临床和遗传学注释的原发或继发骨髓纤维化接受减低强度移植的患者,其中35例为加速期骨髓纤维化。

主要发现

  • 加速期组中位白细胞计数更高,更多患者有体质性症状,RAS突变检出更频繁。
  • 中位随访5.9年,加速期组估计5年总生存率65%(95%CI 49%至81%)vs 慢性期组64%(95%CI 59%至69%),P=0.91,中位总生存未达到。
  • 加速期组估计5年无复发生存率49%(95%CI 32%至67%)vs 慢性期组55%(95%CI 50%至61%),P=0.65。
  • 加速期组估计5年非复发死亡率20%(95%CI 8%至33%)vs 慢性期组30%(95%CI 24%至35%),P=0.25。
  • 加速期组5年复发率30%(95%CI 14%至46%)vs 慢性期组15%(95%CI 11%至19%),P=0.02。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Accelerated-phase myelofibrosis, currently defined by circulating blasts 10% to 19%, usually confers very high risk for progression and poor outcome. The outcome of hematopoietic stem cell transplantation for accelerated-phase myelofibrosis has not been evaluated yet. We analyzed the outcome of 349 clinically and genetically annotated patients with primary or secondary myelofibrosis undergoing reduced intensity transplantation, of whom 35 had accelerated-phase myelofibrosis. In comparison with chronic-phase (<10% blasts) myelofibrosis, median leukocyte counts were higher, more patients had constitutional symptoms, and RAS mutations were detected more frequently in the accelerated-phase group. After a median follow-up of 5.9 years, estimated 5-year overall survival was 65% (95% confidence interval [CI], 49% to 81%) vs 64% (95% CI, 59% to 69%) for the chronic-phase group (P = .91), and median overall survival was not reached. In terms of relapse-free survival, estimated 5-year outcome for the accelerated-phase group was 49% (95% CI, 32% to 67%) vs 55% (95% CI, 50% to 61%) for the chronic-phase group (P = .65). Estimated 5-year nonrelapse mortality was 20% (95% CI, 8% to 33%) for the accelerated-phase group vs 30% (95% CI, 24% to 35%; P = .25) for the chronic-phase group. In terms of relapse, 5-year incidence was 30% (95% CI, 14% to 46%) for the accelerated-phase group vs 15% (95% CI, 11% to 19%) for the chronic-phase group (P = .02). Results were confirmed in multivariable analysis and propensity score matching. In conclusion, reduced intensity transplantation showed excellent survival but higher relapse for accelerated-phase myelofibrosis.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gagelmann N, Wolschke C, Salit RB, et al. Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis. Blood Adv. 2022. PMID: 35051996. doi:10.1182/bloodadvances.2021006827

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。